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Abstract Initiation factor (elF) 4E plays a key role in the 
regulation of translation. Its activity is modulated both by 
phosphorylation and by its association with an inhibitory protein, 
4E-BP1, which precludes its interaction with eIF4G. Although 
increased eIF4E phosphorylation has been correlated with the 
activation of protein synthesis in T cells, the kinase(s) and/or 
phosphatase(s) involved have not been characterised. There is 
evidence for phosphorylation of eIF4E mediated by both protein 
kinase C-dependent and -independent signalling pathways. In 
these studies, I show that activation of protein kinase C with 
phorbol ester, stimulation via the T cell receptor complex with 
the monoclonal antibody OKT3 and cellular stresses increase the 
phosphorylation of eIF4E in Jurkat T cells. In contrast to 
published data, inhibition of either the ERK MAP kinase or p38 
MAP kinase signalling pathways does not affect the PMA- or 
OKT3-stimulated increase in eIF4E phosphorylation. However, 
simultaneous inhibition of both of these pathways with selective 
inhibitors is required to completely abrogate the enhanced 
phosphorylation of eIF4E. These data show that in Jurkat cells, 
protein kinase C modulates the phosphorylation status of eIF4E 
indirectly via the ERK and/or p38 MAP kinase signalling 
pathways. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The T cell antigen receptor complex (TCR-CD3) mediates 
signalling pathways that can result in activation, anergy or 
apoptosis, the outcome depending upon the T cell differentia-
tion state and the nature of the signals transmitted by co-
receptors (reviewed in [1,2]). The TCR is coupled to a protein 
tyrosine kinase (PTK) cascade that links the TCR-CD3 to at 
least three signalling cascades: the guanine nucleotide binding 
protein, ras, phospholipase Cyl (PLCyl) and the c-jun N-ter-
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minal kinase/stress activated protein kinase (JNK/SAPK) [1-
4]. Activation of ras via signalling through the TCR-CD3 
complex plays a central role in the regulation of mitogen-
activated 2r°tein (MAP) kinases (such as ERK1, ERK2) 
and JNK/SAPK [1-4]. PLCyl controls the metabolism of in-
ositol phospholipids, thereby generating inositol polyphos-
phates that mobilise intracellular calcium and diacylglycerol 
that stimulates protein kinase C (PKC) [2]. Synergistic inter-
actions between ras, PKC, JNK/SAPK and calcium-con-
trolled signalling pathways are necessary for TCR signal 
transduction [4]. In many cells, activation of MAP kinases 
serves as an integration point for both PTK and PKC signal-
ling pathways, although the role of the latter in this response 
has been the subject of much debate [5]. 
When T cells are stimulated through the TCR-CD3 com-
plex with a monoclonal antibody (OKT3), or with mitogens 
such as phorbol esters (PMA, phorbol 12-myristate 13-ace-
tate) and calcium ionophores (ionomycin) which mimic this 
effect, the rate of protein synthesis is greatly increased and 
activation of intracellular signalling pathways utilising tyro-
sine kinases and protein kinase C (PKC) results in increased 
phosphorylation of eIF4E and stimulated initiation factor 
complex formation [6,7]. Physiological regulation of protein 
synthesis is almost always exerted at the level of polypeptide 
chain initiation, mediated in part by phosphorylation events 
that modulate the availability of initiation factors to partic-
ipate in the initiation process (reviewed in [8,9]). The cap 
structure present at the 5' end of mRNA facilitates mRNA 
binding to the ribosome, promoted by at least three initiation 
factors (eIF4A, 4B, 4F) and ATP hydrolysis [8,9]. eIF4F, a 
cap binding protein complex composed of three subunits [8-
10], is believed to unwind secondary structure in the mRNA 
5' untranslated region to facilitate binding to the 40S riboso-
mal subunit. Although increased levels of eIF4E phosphoryl-
ation correlate directly with enhanced rates of translation in a 
variety of cell types (reviewed in [8]), it is still not clear how 
phosphorylation of eIF4E modulates its activity. The major 
phosphorylation site of eIF4E is serine-209 in vitro and in 
vivo [11-14], and there is evidence for phosphorylation medi-
ated by both protein kinase C-dependent and -independent 
pathways [8]. Protein kinase C will phosphorylate eIF4E in 
vitro at the correct site, albeit at low stoichiometry [15-17]. In 
addition, co-injection of PKC and eIF4E into quiescent NIH 
3T3 cells led to a synergistic effect on eIF4E mitogenic activity 
[18]. Whilst there may be a direct effect of phosphorylation on 
cap structure recognition in vitro [19], phosphorylation of 
eIF4E in vivo can also be correlated with enhanced interac-
tion with other components of the eIF4F complex [6,7,20]. 
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Additional eIF4E binding proteins (e.g. 4E-BP1 and 4E-
BP2) which interact with eIF4E and inhibit cap structure-de-
pendent translation have been identified as downstream sig-
nalling targets [21]. Phosphorylation of 4E-BP1 disrupts its 
interaction with eIF4E, liberating eIF4E to interact with a 
conserved hydrophobic region of e IF4G. A similar sequence 
found in 4E-BP1 is involved in binding to eIF4E and com-
petes with e IF4G for eIF4E binding [22]. Current models 
suggest that the phosphorylation of 4E-BP1 and consequent 
liberation of eIF4E lead to the up-regulation of translation 
[8,21], with association of eIF4E with 4E-BP1 preventing the 
phosphorylation of eIF4E by protein kinase C in vitro [14]. 
The phosphorylation of 4E-BP1 is inhibited by the immuno-
suppressant, rapamycin, which prevents the activation of the 
70 k D a ribosomal protein S6 kinase (p70S6K) signalling path-
way and stabilises the interaction between eIF4E and 4E-BP1 
(see references in [8,9,22]). However, rapamycin does not pre-
vent the phosphorylation of eIF4E in primary pig T cells [7], 
Xenopus oocytes [20], CHO.T cells in response to insulin [23] 
or N I H 3T3 cells in response to serum [24]. 
In order to understand the mechanism of translational ac-
tivation in T cells, I have been studying the role of the P K C 
signalling pathway in the enhanced phosphorylation of eIF4E. 
In Jurkat cells, the enhanced phosphorylation of eIF4E in 
response to activation of protein kinase C is facilitated by 
signalling through the classical M A P kinase and p38 M A P 
kinase pathways, and does not require dissociation of the 
eIF4E/4E-BPl complex. Inhibition of either E R K or p38 
M A P kinase activity alone is not sufficient to block eIF4E 
phosphorylation. However, simultaneous inhibition of both 
E R K and p38 M A P kinase signalling pathways abrogated 
the P M A - or OKT3-stimulated phosphorylation of eIF4E. 
These data indicate that P K C does not directly phosphorylate 
eIF4E in T cells. 
2. Materials and methods 
2.1. Chemicals and biochemicals 
Materials for tissue culture were from Gibco Life Technologies, 
Immobilon PVDF was from Millipore and m7GTP-Sepharose was 
from Pharmacia-LKB. Microcystin and ionomycin were from Calbio-
chem and unless otherwise stated, PMA and all other chemicals were 
from Sigma. Antiserum to eIF4E was as described previously [6,7,20] 
and antiserum specific for ERK, phospho-ERK, p38 and phospho-
p38 were from New England Biolabs. Anti-CD3 monoclonal antibody 
(OKT3) and rapamycin were kind gifts from Dr. J. Kay (Sussex, UK), 
PD98059 was from Parke-Davis and SB203580 was a gift from 
SmithKline Beecham, King of Prussia, PA, USA. 
2.2. Tissue culture 
Human Jurkat T cells were grown in RPMI 1640 with Glutamax 
supplemented with 10% foetal calf serum (FCS) as described previ-
ously [7]. Cell cultures were incubated for 1 h with vehicle alone or 
rapamycin, PD98059 or SB203580 as described in individual figure 
legends, prior to activation. 
2.3. Preparation of cell extracts 
Following treatment, cells were pelleted in a cooled centrifuge, the 
medium removed and cells resuspended in 500 JJ.1 ice-cold buffer A 
(50 mM MOPS-KOH, pH 7.4, 2.5 mM EGTA, 1 mM EDTA, 40 mM 
(3-glycerophosphate, 1 liM microcystin, 120 mM NaCl, 7 mM 2-mer-
captoethanol, 2 mM benzamidine, 1 mM phenylmethylsulphonyl flu-
oride (PMSF), 0.1 mM GTP, 2 mM Na3V04). Following a wash in 
the same buffer, cells were resuspended in 0.1 ml buffer A per 10 ml of 
original culture and lysed by the addition of 0.5% (by vol.) Nonidet 
P-40 and vortexing. Cell debris was removed by centrifugation in a 
microfuge for 5 min at 4°C and the resultant supernatant was frozen 
in liquid N2. 
2.4. Polyacrylamide gel electrophoresis (SDS-PAGE), vertical slab 
isoelectric focusing ( VSIEF) and immunoblotting 
One-dimensional polyacrylamide gels and vertical slab isoelectric 
focusing gels were run as described [7,20]. Proteins transferred to 
PVDF and elFE, ERK, phosphorylated ERK, p38 and phosphoryl-
ated p38 MAP kinases were detected with specific rabbit anti-peptide 
antisera as described in the individual figure legends. 
2.5. m7GTP-Sepharose chromatography 
For the isolation of eIF4E and associated proteins, cell extracts of 
equal protein concentration were subjected to m7GTP-Sepharose 
chromatography as described [6,7,20]. The beads were washed three 
times in buffer A and bound protein eluted with either SDS-PAGE or 
VSIEF sample buffer, as indicated. 
2.6. Assay for protein kinase C activity in cell extracts 
For assays of protein kinase C activity, incubations (total volume 
20 ul) contained 50 mM MOPS pH 7.2, 5 mM MgCl2, 1 mM dithio-
threitol, 40 ug/ml leupeptin, 500 nM PKI (peptide inhibitor of protein 
kinase A), 2 mM CaCl2, 1 mM EDTA, 100 |iM [y-
32P]ATP 
(16800 cpm/pmol), 37.5 ug/ml phosphatidylserine, 75 nM PMA and 
8 ug of cell extract. Reactions were initiated by the addition of 10 uM 
of the protein kinase C-specific substrate peptide FKKSFKL (Ba-
chem, Switzerland), designed after the known phosphorylation site 
of the myristoylated alanine-rich C-kinase substrate protein 
(MARCKS) [25], in the absence or presence of 400 uM of the protein 
kinase C-specific pseudosubstrate inhibitor peptide, RFARK-
GALRQKNVHDVKQ [26] and incubated for 20 min at 30°C. Reac-
tions were moved into ice and stopped with the addition of 10 ul 0.5% 
(by vol.) phosphoric acid containing 5 mM adenosine. Samples (15 ul) 
were spotted onto P81 ion-exchange paper, which was washed three 
times in 0.5% phosphoric acid, once in acetone, dried and counted 
with liquid scintillant 
3. Results and discussion 
3.1. PMA and OKT3 stimulate the phosphorylation of eIF4E 
Despite growing evidence for a role for phosphorylation of 
eIF4E in translational control in T cells [6-8], the kinase(s) 
responsible for enhanced eIF4E phosphorylation in vivo and 
Table 1 
Incubation with PD98059 and SB203580 does not prevent the activation of protein kinase C 
Treatment 
Unstimulated 
PMA 
OKT3 
PMA+PD98059+SB203580 
Phosphorylation of peptide substrate (pmol/min/ng protein) Fold increase over unstimulated 
1.5 
14 
7.6 
10.5 
1 
9.3 
5 
7 
Jurkat T cells (10 ml culture) were preincubated with vehicle, or 20 uM SB203580 and 50 uM PD98059 for 1 h, prior to incubation with or without 
20 nM PMA or OKT3 for 15 min, as indicated. Cell extracts were prepared and assayed for their ability to phosphorylate a PKC-specific peptide 
[25], in the absence or presence of a pseudosubstrate peptide inhibitor of PKC [26], as described in Section 2. The activity of PKC assayed by 
incorporation of [32P]phosphate into the MARCKS peptide is expressed as pmol/min/ng protein after subtraction of PKC activity recovered in the 
presence of the pseudosubstrate inhibitor. Under these assay conditions, the pseudosubstrate inhibitor peptide decreased the activity of recombinant 
PKCa by 97% (data not shown). 
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Fig. 1. Phosphorylation of eIF4E is stimulated in response to PMA, 
OKT3 and cellular stress. A: Jurkat T cells (10 ml culture), grown 
for 4 days to high density to reduce the background level of eIF4E 
phosphorylation [7], were incubated in the presence of PMA 
(20 nM) or OKT3 (5 u.g/ml) for the indicated times. Cells were 
transferred to ice and extracts prepared as described. Total eIF4E 
was isolated from aliquots (25 u.1) of equal protein concentration by 
m7GTP-Sepharose chromatography and the phosphorylation status 
of recovered protein monitored by VSIEF and immunoblotting. The 
more phosphorylated variant in this gel system is the upper band, 
as indicated on the right. These data are representative of those ob-
tained in three separate experiments. B: Jurkat T cells (10 ml) were 
incubated for 15 min without further addition (lane 5), for 5 min in 
the presence of 5 mM sodium arsenite (lane 1) or 10 |xg/ml aniso-
mycin (lane 2), or for 15 min with 20 nM PMA/100 nM ionomycin 
(lane 3), 0.5M sorbitol (lane 4) or 1 uM okadaic acid (lane 6). Cell 
extracts were prepared and eIF4E isolated and subjected to VSIEF 
and immunoblotting as above. These data are representative of 
those obtained in three separate experiments. C: Jurkat T cells were 
incubated in the absence or presence of 20 nM PMA (•) or 5 ug/ml 
OKT3 (□) as described above. At each time point, the percentage 
of total eIF4E in the phosphorylated form was determined by scan-
ning densitometry. The amount of eIF4E in the phosphorylated 
form in unstimulated cells at 30 min incubation was 4% (±2%, 
n = 3). Presented data are the means and S.D. (bars) of three sepa-
rate experiments. D: Jurkat T cells were incubated for the indicated 
times in the absence or presence of 5 mM sodium arsenite (o), 
20 nM PMA/100 nM ionomycin (•) or 10 |ig/ml anisomycin (□) 
and the percentage of total eIF4E in the phosphorylated form was 
determined as above. Presented data are the means and S.D. (bars) 
of three separate experiments. 
the signalling pathways utilised remain elusive. There is, how-
ever, evidence for a role of protein kinase C in these processes, 
as eIF4E is phosphorylated in vivo in response to PMA in 
reticulocytes, 3T3-L1 cells, T cells and CHO.T cells [6-8,15-
17,23], and in vitro by protein kinase C [14-17]. I now report 
the results of experiments designed to address the question as 
to whether PKC directly phosphorylates eIF4E in T cells, or 
whether enhanced phosphorylation of eIF4E is mediated via 
downstream signalling pathways, particularly those involving 
members of the MAP kinase family. 
To look at the effect of activation of PKC and stimulation 
of the TCR-CD3 receptor complex on the phosphorylation of 
eIF4E, Jurkat T cells were incubated with either 20 nM PMA 
or 5 u.g/ml OKT3 (half maximal concentrations of agonist 
(data not shown)), for various times prior to the preparation 
of extracts. Total cytoplasmic eIF4E was then isolated by 
m7GTP-Sepharose chromatography and bound protein sub-
jected to VSIEF and immunoblot analysis. With this gel sys-
tem, the upper immunoreactive band represents the more 
phosphorylated variant of eIF4E [7,14,20,23]. Fig. 1A shows 
that activation of PKC with 20 nM PMA led to enhanced 
levels of eIF4E phosphorylation from 3% in control cells to 
20% within 5 min, reaching 50% of total eIF4E in the phos-
phorylated state at 30 min (see Fig. 1C). The response of 
eIF4E phosphorylation to OKT3 was slightly more rapid 
(28%o at 5 min) and was maximal at 15 min (42%; Fig. 1C). 
Increased phosphorylation of eIF4E in response to PMA ap-
parently did not require the dissociation of eIF4E from 4E-
BP-1 (data not shown), suggesting that association of eIF4E 
with 4E-BP-1 does not preclude its phosphorylation in vivo. 
This is contrary to the in vitro studies of Whalen et al. [14], 
who have shown that association of recombinant 4E-BP1 with 
eIF4E prevents the phosphorylation of the latter by protein 
kinase C. 
3.2. Cellular stress and okadaic acid increase the 
phosphorylation of eIF4E 
In addition to phosphorylation of target proteins that may 
be attributed directly to it, PKC is also likely to contribute to 
cellular signalling events through cross-talk with other cas-
cades. These include the activation of the classical (ERK1 
and ERK2) MAP kinases, the JNK/SAPK MAP kinase and 
possibly the p38 MAP kinase family [27]. In fibroblasts, stress-
es induced by arsenite and sorbitol have been reported to 
strongly induce p38 MAP kinase but not the classical 
(ERK1, ERK2) MAP kinases (reviewed in [27] and references 
therein). To examine the potential role of these MAP kinase 
signalling pathways in modulating the phosphorylation of 
eIF4E in T lymphocytes, Jurkat cells were incubated in the 
absence or presence of 5 mM arsenite, 10 |J,g/ml anisomycin, 
20 nM PMA/100 nM ionomycin, or 0.5 M sorbitol for the 
times indicated. Extracts were prepared and the phosphoryl-
ation status of eIF4E monitored by VSIEF and immunoblot-
ting. Fig. 1B,D shows that arsenite caused an increase in 
eIF4E phosphorylation from 4% in the control cells (Fig. 
IB, lane 5) to 7%> in the presence of arsenite at 5 min exposure 
(lane 1), rising to 31% by 30 min (Fig. ID). PMA/ionomycin 
increased the phosphorylation of eIF4E to 42% at 30 min 
(Fig. IB, lane 3; Fig. ID), whilst anisomycin resulted in a 
more rapid increase in eIF4E phosphorylation at early times 
of incubation (Fig. IB, lane 2; Fig. ID). Under these condi-
tions, sorbitol had little effect on the phosphorylation of 
eIF4E at early times of incubation (Fig. IB, lane 4). The 
phosphatase inhibitor, okadaic acid [28,29] was found to in-
crease eIF4E phosphorylation to a level similar to that caused 
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by P M A (Fig. IB, lane 6), suggesting that phosphate turnover 
is important in modulat ing the level of eIF4E in the phos-
phorylated form in these cells. 
3.3. The PMA-induced phosphorylation of eIF4E involves both 
ERK and p38 MAP kinase pathways 
Previous studies have shown that treatment of T cells with 
P M A or activation of the T C R - C D 3 complex predominantly 
results in the activation of the classical M A P kinase, E R K 2 
[5,30]. In numerous cell types, activation of E R K 1 and E R K 2 
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Fig. 3. Protein kinase C does not directly phosphorylate eIF4E in 
Jurkat T cells. A: Jurkat T cells (10 ml culture) were preincubated 
with vehicle ( - ) , 20 uM SB203580, 50 uM PD98059 or 20 nM ra-
pamycin for 1 h, prior to incubation with or without 20 nM PMA 
for 30 min, as indicated. Cell extracts were prepared and aliquots of 
equal protein concentration (25 ul) were subjected to m7GTP-Se-
pharose chromatography to isolate total eIF4E. The recovered pro-
tein was subjected to VSIEF and eIF4E visualised by immunoblot-
ting; the more phosphorylated variant (P) is indicated on the right. 
These data are representative of those obtained in three separate ex-
periments. B: Jurkat cells (10 ml culture) were preincubated in the 
absence or presence of inhibitors, as described above, and incubated 
in the absence or presence of 5 ug/ml OKT3 for 15 min prior to 
preparation of extracts. eIF4E was isolated and visualised as de-
scribed in A. These data are representative of those obtained in 
three separate experiments. 
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Fig. 2. PMA and OKT3 enhance the phosphorylation of p38 MAP 
kinase. A: Jurkat T cells (10 ml culture) were preincubated for 1 h 
with vehicle alone (lane 1), 50 u.M PD98059 alone (lane 5), 20 uM 
SB203580 alone (lanes 3, 6) or 50 uM PD98059 and 20 uM 
SB203580 (lanes 4, 7), prior to the addition of vehicle (lane 1), 
20 nM PMA (lanes 2, 5-7) or 1 uM okadaic acid (lane 8) for 
15 min. Extracts were prepared and aliquots (2 ul for ERK; 4 ill 
for p38 MAP kinase) of equal protein concentration were subjected 
to SDS-PAGE. ERK1 and ERK2 in the non-phosphorylated form 
(ERK) or phosphorylated on tyrosine 204 (P-ERK) were visualised 
by immunoblotting using specific antiserum (upper panel). The level 
of ERK in the phosphorylated (and hence activated form) was 
quantified as described above and expressed as fold increase over 
that present in non-stimulated cells (lower left, filled bars). In a sim-
ilar manner, p38 and p38 phosphorylated on threonine-180/tyrosine-
182 were visualised by SDS-PAGE and immunoblotting (data not 
shown) and the results are quantified in the lower right panel (open 
bars). Presented data are the means and S.D. (bars) of three sepa-
rate experiments. In both cases, these phosphorylation events corre-
spond to catalytic activation of ERK and p38 MAP kinases [27]. 
B: Jurkat T cells (10 ml culture) were preincubated for 1 h with ve-
hicle alone (lane 1), or 20 uM SB203580 (lanes 3, 4), prior to the 
addition of vehicle (lane 1), 5 ug/ml OKT3 (lanes 2, 4) or 10 ug/ml 
anisomycin (lane 5) for 10 min. Extracts were prepared and aliquots 
(4 u.1) of equal protein concentration were subjected to SDS-PAGE 
and total p38 (upper panel) and phosphorylated p38 (lower panel) 
visualised as in A. These data are representative of those obtained 
in four separate experiments. 
is prevented by the specific upstream (MEK1) kinase inhibi-
tor, PD98059 (reviewed in [31]). In addition, PMA/ionomycin 
or O K T 3 and CD28 cause a transient activation of JNKV 
SAPK which is required for full T cell activation [4], an effect 
not observed with P M A alone [30]. Similar activation of JNKV 
SAPK has been reported for y-radiation [32] and antioxidant 
treatment of T cells [33]. Arsenite, bacterial lipopolysaccha-
ride, heat shock and interleukin-1 predominantly activate the 
p38 M A P kinase pathway [27,31], which itself leads to the 
activation of a family of downstream kinases [31,34]. Re-
cently, it has been demonstrated that platelet-derived growth 
factor [35] can activate p38 M A P kinase in airway smooth 
muscle cells and that T cell proliferation in response to inter-
leukins 2 and 7 requires p38 M A P kinase activation [36]. At 
least two of the isoforms of the p38 M A P kinase family are 
selectively inhibited by the compound SB203580 [31,34,37,38]. 
Although P M A results in a modest activation of some mem-
bers of this family of kinase [38,39], the physiological rele-
vance of this is not known at this time. 
In order to determine whether P K C was directly or indi-
rectly stimulating the phosphorylation of eIF4E in Jurkat T 
cells, the selective inhibitors PD98059, SB203580 and the 
phosphatase inhibitor okadaic acid [28,29] were employed. 
Activation of E R K 1 , E R K 2 and p38 kinases (Fig. 2A) was 
monitored by SDS-PAGE and immunoblott ing using tyrosine 
phosphorylation-specific antisera to these proteins. A parallel 
immunoblot with an antiserum which recognises total E R K or 
p38 M A P kinase protein was included as a control to show 
similar loading of cell lysates. Fig. 2A shows that, relative to 
unstimulated cells (lane 1), treatment with P M A (lane 2), or 
okadaic acid (lane 8) resulted in a large increase (7.5-fold) in 
the tyrosine phosphorylation (and hence activation) of E R K 1 
and E R K 2 kinases [34,36,39]. In addition, P M A (lane 2) led 
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to a small (2.2-fold), but reproducible activation of p38 MAP 
kinase (quantified in Fig. 2A, right panel). With PMA, the 
activation of ERK kinase was severely inhibited by preincu-
bation of cells with the MEK1 inhibitor, PD98059 (lane 5), 
and, in agreement with published data [31,34,38] ERK kinase 
activation was less sensitive to SB203580 (lane 6). Addition of 
either SB203580 (lane 3) or SB203580 and PD98059 (lane 4) 
in the absence of PMA had little effect on ERK or p38 MAP 
kinase activity. Addition of both PD98059 and SB203580 to 
cells prior to activation with PMA inhibited the activation of 
ERK and p38 MAP kinases (lane 7). Similar results were 
obtained when ERK kinase activity was monitored using im-
munocomplex assays with a synthetic peptide as substrate 
(data not shown). Fig. 2B shows the effect of stimulation 
via the TCR-CD3 complex on the activation of p38 MAP 
kinase, monitored by SDS-PAGE and immunoblotting using 
phosphorylation-specific antiserum. As with PMA (Fig. 2A), 
relative to unstimulated cells (Fig. 2B, lane 1), treatment with 
OKT3 (lane 2) resulted in over a 2-fold increase in phospho-
rylation (and hence activation) of p38 MAP kinase. Under 
similar conditions anisomycin (lane 5) induced a 4.8-fold in-
crease in p38 MAP kinase activation. The selectivity of 
SB203580 was confirmed by the finding that it prevented the 
basal level of activation of p38MAP kinase (lane 3), activation 
observed in the presence of OKT3 (lane 4), and the p38-medi-
ated phosphorylation of MAPKAP-K2 and HSP27 ([31], data 
not shown). 
To look at the effect of inhibition of these MAP kinase 
signalling pathways on the ability of PMA to stimulate the 
phosphorylation of eIF4E, cells were preincubated with or 
without inhibitor prior to addition of PMA for 30 min. Cell 
extracts were prepared, eIF4E isolated by m7GTP-Sepharose 
chromatography and the phosphorylation status of recovered 
eIF4E monitored by VSIEF. Fig. 3A shows that as expected, 
the phosphorylation of eIF4E was enhanced in response to 
PMA (compare lanes 1 and 6). This PMA-increased phos-
phorylation of eIF4E was unaffected by pretreatment with 
SB203580, PD98059 or rapamycin alone (lanes 7-9). The 
lack of effect of rapamycin on the phosphorylation of eIF4E 
is consistent with studies utilising primary pig T cells [7], Xe-
nopus oocytes [20], CHO.T cells in response to insulin [23] or 
NIH 3T3 cells in response to serum [24,40]. However, the 
PMA-stimulated phosphorylation of eIF4E was completely 
abrogated by the simultaneous inhibition of the ERK and 
p38 MAP kinase signalling pathways (lane 10). The inhibitors 
alone did not affect the phosphorylation status of eIF4E (Fig. 
3A, lanes 2-5) and only preincubation with rapamycin af-
fected the association of eIF4E with its inhibitory partner, 
4E-BP1 (data not shown). 
As stimulation of the TCR-CD3 complex also resulted in 
the enhanced phosphorylation of eIF4E, I have analysed the 
effect of inhibition of the ERK and p38 MAP kinase path-
ways in this response. As shown in Fig. 3B, increased phos-
phorylation of eIF4E in response to OKT3 (compare lanes 1 
and 5) was unaffected by preincubation of cells with SB203580 
or PD98059 alone (lanes 6 and 7). However, the OKT3-stimu-
lated increase in phosphorylation of eIF4E was completely 
abrogated when signalling through both the ERK and p38 
MAP kinases was inhibited (compare lanes 5 and 8). As 
shown with PMA (Fig. 2A), preincubation of cells with these 
inhibitors prior to stimulation with OKT3 prevented the acti-
vation of ERK and p38 MAP kinases (Fig. 2B). 
These data suggest that PKC is indirectly involved in the 
phosphorylation of eIF4E. Whilst unlikely to affect the activ-
ity of PKC alone [31,34,38], an alternative explanation is that 
SB203580 and PD98059 together inhibit PKC activity in the 
cell. To discount this possibility, PKC activity was assayed in 
cell extracts using a PKC-specific peptide substrate designed 
after the known phosphorylation site of the MARCKS [25]. 
To further address the specificity of this substrate peptide for 
PKC, reactions were carried out in the presence of a PKC-
specific pseudosubstrate inhibitor peptide, which prevents 
both autophosphorylation and substrate phosphorylation by 
PKC in vivo [26]. Table 1 shows that treatment of Jurkat cells 
with PMA for 15 min resulted in a 9.3-fold increase in PKC-
specific phosphorylation of the peptide substrate, whilst 
OKT3 induced a 5-fold activation. Preincubation of cells 
with PD98059 and SB203580 for 1 h prior to stimulation 
with PMA resulted in activation of protein kinase C to 75% 
of the level observed in the absence of inhibitors. These data 
suggest that the combination of PD98059 and SB203580 did 
not prevent the activation of total PKC in these cells, 
although specific effects on individual isotypes of PKC cannot 
be discounted. 
These data indicate that activation of protein kinase C re-
sults in increased levels of eIF4E phosphorylation, which oc-
curs indirectly via the ERK and p38 MAP kinase signalling 
pathways. Similar results have been obtained upon PMA 
stimulation of primary human T cells (M. Bushell and S. 
Morley, unpublished data) and Xenopus kidney cells in culture 
(C. Fraser and S. Morley, unpublished data). Recently, PMA 
has been shown to activate p38 MAP kinase in a cytokine-
dependent T cell line [36], transfected COS-7 [37] and HeLa 
cells [39] to a level similar to that described for Jurkat cells 
(Fig. 2A). In all cases, this may be mediated by common 
kinase(s) and/or phosphatase(s) which integrate multiple ex-
tracellular signals necessary for the activation of ternary com-
plex factors, c-fos transcription [31,41] and the enhanced 
phosphorylation of eIF4E [31,40]. Such would be consistent 
with the recent report that Mnkl/Mnk2 (MAP kinase-inter-
acting kinases 1 and 2), which are downstream of multiple 
MAP kinase pathways, mediate the insulin-induced and 
stress-induced phosphorylation of eIF4E [42,43], with Mnkl 
able to phosphorylate eIF4E at the correct site in vitro [42]. 
Whilst phorbol ester increased the activity of Mnkl expressed 
in 293 cells [42], this was prevented by either PD98059 or 
SB203580 alone. In HeLa cells, phorbol ester-stimulated ac-
tivity of expressed Mnkl was largely prevented by inhibition 
of the ERK MAP kinase pathway alone [43]. However, in 
Jurkat cells stimulated with either PMA, inhibition of both 
the ERK and p38 MAP kinase signalling pathways was re-
quired to abrogate eIF4E phosphorylation in vivo (Fig. 3). 
These data suggest that PMA activates both the ERK and 
the p38 MAP kinase pathways in T cells, and that signalling 
via either is sufficient for the physiological phosphorylation of 
eIF4E. 
At this time, the potential role of Mnkl in this response is 
unclear, as eIF4E kinase(s) activity, monitored with recombi-
nant eIF4E protein, was only increased by 1.2-fold with PMA 
(data not shown). Consequently, this has made any possible 
biochemical identification of putative eIF4E kinase(s) difficult. 
The finding that okadaic acid alone induced the phosphoryl-
ation of eIF4E to a level similar to PMA (Fig. IB) suggests 
that regulation may be directly at the level of phosphatase(s). 
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Indeed, it has recently been shown that arsenite, acting via the 
p38 M A P kinase pathway, stimulates AP-1 transcription fac-
tor activity by inhibiting a constitutive phosphatase [44]. Al-
ternatively, as okadaic acid has been shown to activate both 
E R K [27-29] (Fig. 2A) and p38 M A P kinase (data not 
shown), these data may also reflect effects at the level of 
M n k l / M n k 2 . The identity of putative eIF4E kinase(s) and 
phosphatases(s) downstream of the E R K and p38 M A P ki-
nases, and the relative importance of such signalling pathways 
in T cells is currently under investigation. 
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